Código QR (código de barras bidimensional)

Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin’s disease developing resistance to pembrolizumab

Targeted chemotherapy and immune checkpoint inhibitors (ICPi) have expanded the spectrum of therapies for patients with relapsed/refractory (r/r) Hodgkin’s disease and significantly improved the proportion of patients with long-term disease control. However, there is no standardized therapeutic opti...

ver descrição completa

Na minha lista:
Principais autores: K. Reuthner, P. Aubele, K. Menhart, P. Rath, D. C. Harrer, W. Herr, J. Hahn, M. Vogelhuber, D. Heudobler, F. Lueke, A. Reichle, M. Grube
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2024-02-01
coleção:Frontiers in Pharmacology
Assuntos:
Hodgkin`s disease
relapse
pembrolizumab
resistance
MEPED
remission
Acesso em linha:https://www.frontiersin.org/articles/10.3389/fphar.2024.1334233/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados